Lung cancer is amongst the most pervasive malignancies having high mortality rates. It is
broadly grouped into non-small-cell lung cancer (NSCLC) and small-cell lung cancer …

EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on
approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates - PMC Back …

The current standard-of-care for the treatment of advanced non-small cell lung cancer
(NSCLC) incorporates targeted therapies, immune-checkpoint inhibitors (ICI) and systemic …

HER2 mutations, which account for 2–4% of non-small cell lung cancer (NSCLC), are
distinct molecular alterations identified via next generation sequencing (NGS). Previously …

Current literature review on the tumor immune micro-environment, its heterogeneity and future
perspectives in treatment of advanced non-small cell lung cancer - PMC Back to Top Skip to …

Lung cancer is the prime cause of cancer-related deaths globally, with a contribution of 85%
from non-small cell lung cancer. Before a few decades back, conventional chemotherapy …

In recent decades, there has been a surge in the approval of monoclonal antibodies for
treating a wide range of hematological and solid malignancies. These antibodies exhibit …

Abstract Introduction According to current International Association for the Study of Lung
Cancer guideline, physicians may first use plasma cell‐free DNA (cfDNA) methods to …

Pyrotinib is a novel epidermal growth factor receptor/human epidermal growth factor
receptor-2 (HER2) tyrosine kinase inhibitor that exhibited clinical efficacy in patients with …

Metastatic breast cancer demonstrates HER2/neu amplification approximately 15% of the
time. However, HER2 mutations, which often stimulate tumor growth, occur in only 3% to 5 …